Purpose: Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.
Materials And Methods: A thorough examination of existing literature has been conducted on PubMed.
Results: PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.
Conclusions: Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13685538.2023.2288347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of PDE-5 inhibitors used in erectile dysfunction with some candidate molecules: A study involving molecular docking, ADMET, DFT, biological target, and activity.
BMC Urol
March 2025
Energy Systems Engineering Department, Engineering Faculty, Adana Alparslan Türkeş Science and Technology University, Adana, 01250, Türkiye.
Erectile dysfunction (ED) is a urological condition defined as the inability of a man to achieve or maintain an erection. This condition negatively affects his sexual performance and the performance of his partner. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to treat ED.
View Article and Find Full Text PDFUnusual Cardiovascular Response to Sildenafil: Complete Heart Block in a Healthy Young Adult.
Cureus
February 2025
Emergency Medicine, Charnock Hospital, Kolkata, IND.
Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, is widely used for erectile dysfunction and pulmonary hypertension, with its cardiovascular safety profile being well documented. However, its potential to induce conduction abnormalities remains largely unexplored, both due to a lack of clinical reports and limited mechanistic studies. While tachyarrhythmias have been frequently associated with sildenafil use, bradyarrhythmias, particularly complete heart block, are an unreported complication.
View Article and Find Full Text PDFSchistosomiasis is the second most dangerous parasitic disease, affecting approximately 200 million people worldwide. Chronic Schistosomiasis, especially the hepatosplenic form, can lead to the development of pulmonary arterial hypertension and has been classified as a distinct entity referred to as "Schistosomiasis-associated pulmonary arterial hypertension" (Sch-PAH). Several mechanisms may play a role in the pathogenesis of Sch-PAH, which include peri-ovular granulomatous inflammation with subsequent vascular remodeling.
View Article and Find Full Text PDFComprehensive characterization of the chemical composition of Ela tablet and its metabolites, with molecular docking screening of potential bioactive components for erectile dysfunction treatment.
J Pharm Biomed Anal
February 2025
State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, PR China; University of Chinese Academy of Sciences, No. 19 (A) Yuquan Road, Shijingshan District, Beijing 100049, PR China. Electronic address:
Erectile dysfunction (ED) is a disorder involving both physiological and psychological implications, and phosphodiesterase 5 (PDE5) inhibitors serve as the primary treatment. The Ela tablet, a traditional herbal formulation, has demonstrated promising PDE5 inhibitory effects, yet its bioactive constituents and metabolic fate remain unclear. A four-step strategy combining offline two-dimensional supercritical fluid chromatography (SFC) and ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS) was established to characterize the chemical composition of the Ela tablet.
View Article and Find Full Text PDFBritish Society for Sexual Medicine (BSSM) Position statement on Premature Ejaculation.
World J Mens Health
February 2025
Department of Urology, Spire Little Aston Hospital, Birmingham, UK.
To provide an evidence based consensus on the diagnosis and management of premature ejaculation (PE). The British Society for Sexual Medicine (BSSM) takes issue with the advice to use off label treatments, such as daily selective serotonin reuptake inhibitors treatment, favoring on-demand dapoxetine. There is increasing evidence for the use of PDE5 inhibitors which are superior to a placebo for the treatment of PE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!